ALiEM - Pharm Pearls

OCTOBER 11, 2024

Immune thrombocytopenia (ITP) is an acquired autoimmune disorder caused by autoantibodies against platelet antigens. Common inciting events include viral infections, autoimmune diseases, or immunodeficiency syndromes [1]. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Physical Exam Vitals : 98.3°F;

Immunization 152

Immunization Immunity 152

pharmaphorum

JANUARY 15, 2021

Latest data give hope that the vaccine could be added to the campaign after phase 1/2a data showed that the shot provided an immune response that lasted for at least 71 days, the duration of time measured in the study involving patients aged 18-55 years. J&J expects to file with the FDA first, followed by other regulators.

Vaccines 119

Vaccines Immunity Immunization 119

European Pharmaceutical Review

AUGUST 2, 2023

This is an additional ingredient designed to trigger a stronger immune response. The vaccine demonstrated a strong immune response in the trial. In a clinical trial, this vaccine was shown to faciliate a strong immune response against the Omicron BA.1 1 variant, in addition to the original 2020 strain.

Vaccines 98

Vaccines Immunity Immunization 98

European Pharmaceutical Review

JULY 13, 2023

The field of immunotherapy is constantly evolving with the ultimate goal to develop new treatments that help the body’s immune system fight cancer. Immune cells, such as T cells and natural killer (NK) cells, have the inherent ability to combat diseases, including cancer, but are often inhibited by the body’s own suppressive mechanisms.

Immunity 98

Immunity Immunization Hospitals 98

PharmaShots

APRIL 5, 2023

Shots: The P-IIb dose-finding study evaluates vidofludimus calcium vs PBO in patients at 78 study sites in the US and EU The 50wk. maintenance phase results showed a dose-linear increase in clinical remission, 10 & 30mg, qd of vidofludimus calcium showed clinical remission rate (42.3% & 61.5%

Immunization 40

Immunization Immunity 40

European Pharmaceutical Review

MARCH 26, 2024

Moderna’s next-generation COVID-19 vaccine mRNA-1283 demonstrated a higher immune response against SARS-CoV-2, interim results from the company’s Phase III trial show. These findings were based on data comparing the treatment to mRNA-1273.222 (Spikevax ® ), Moderna’s licensed vaccine for the condition.

Vaccines 110

Vaccines Immunization Immunity 110

Pharmaceutical Technology

NOVEMBER 14, 2022

In lupus, the body’s immune system starts to attack its own cells. Saphnelo is also being studied in a Phase III trial in lupus nephritis, where a person’s immune system targets the kidneys, eventually leading to kidney failure. As per AstraZeneca's recent Q3 earnings, Saphnelo has yielded $69 million to date this year.

Immunity 144

Immunity Immunization 144

European Pharmaceutical Review

JUNE 27, 2023

Participants with greater than 90 days of follow-up had elimination of severe hypoglycaemic events in the evaluation period. It is delivered by an infusion into the hepatic portal vein and requires chronic immunosuppressive therapy to protect the islet cells from immune rejection. This eliminates the need for immunosuppression.

Diabetes 98

Diabetes Immunization Immunity 98

pharmaphorum

NOVEMBER 29, 2022

Amplifying and reinvigorating persistent T cell immunity has become a much-needed path to enhance anti-tumor efficacy. T cells are known to mediate anti-tumor immune responses. For that reason, they have become the key target of immune checkpoint therapies, like PD-(L)1 agents. No serious adverse events were observed.

Immunization 105

Immunization Immunity Chemotherapy Compounding 105

Safe Biologics

FEBRUARY 4, 2025

Steqeyma is a human IL-12 and -23 antagonist indicated for multiple immune-mediated diseases, including psoriasis (PsO), psoriatic arthritis (PsA), Crohn’s disease (CD), ulcerative colitis (UC) in adults, and PsO and PsA in pediatric patients 6 years of age and older. Missed last month’s ASBM Newsletter? Read it here.

Biosimilars 130

Biosimilars Immunity Immunization 130

pharmaphorum

APRIL 12, 2021

Preclinical and early clinical data for modulators of the STING & TLR plus other innate immune checkpoint inhibitors has been hugely promising. View the event guide now for the full agenda details and speaker faculty. View the full event guide now. The post STING & TLR Targeting Therapies Summit appeared first on.

Immunization 52

Immunization Immunity Drug Development 52

pharmaphorum

SEPTEMBER 11, 2022

With the results in hand, the developers of the therapy – from the Netherlands Cancer Institute and Norway’s National Center for Cancer Immune Therapy – say they now intend to file for regulatory approvals in Europe before the end of the year, without a commercial partner “to try to ensure that it remains affordable.”

Immunity 105

Immunity Immunization Chemotherapy Hospitals 105

pharmaphorum

NOVEMBER 27, 2024

The 10th Innate Killer Summit is a premier event organised by Hanson Wade, bringing together experts and thought leaders in the field of innate immunity and natural killer cells. Learn more about this event and how it can benefit you.

Immunization 52

Immunization Immunity 52

pharmaphorum

FEBRUARY 8, 2021

It works by using inactivated viral particles to expose the immune system, which mounts an immune response that fights off the active virus in the event of an infection. Brazilian clinical trial results published last month showed the vaccine, dubbed Coronavac, is just over 50% effective.

Vaccines 90

Vaccines Immunization Immunity 90

Pharmacy Times

APRIL 30, 2024

According to the speaker, the complexity of immune-related adverse events resulting from immune checkpoint inhibitors requires a lot of collaborative discussion between patients and providers.

Immunization 26

Immunization Immunity 26

Pharmacy Joe

DECEMBER 18, 2024

The most common causes of acute liver failure were: viral hepatitis, drug-induced (but not from acetaminophen), auto-immune hepatitis and cause indeterminate. Only 1 of the 5 studies suggested an increase in adverse events with treatment, and this was only nausea and vomiting related events.

Hospitals 97

Hospitals Inpatient Immunity Immunization 97

pharmaphorum

APRIL 16, 2021

The 2 nd Gene Therapy Immunogenicity Summit is the industry’s definitive forum enabling you to better modulate, measure and predict immune response to your gene therapy candidate. View the full event guide now for full meeting details! Regulatory considerations for immune responses to gene therapies with the US FDA.

Immunity 52

Immunity Immunization 52

Pharmacy Times

SEPTEMBER 14, 2023

Compared with COVID-19 vaccination alone, recent study findings show health care workers who received both a COVID-19 booster and influenza vaccinations did not have lower immune response or more frequent adverse events.

Vaccines 55

Vaccines Immunization Immunity 55

European Pharmaceutical Review

OCTOBER 7, 2022

UC is an Inflammatory Bowel Disease (IBD) that makes immune system attack the gastrointestinal (GI) tract. Zeposia ® reduces the capacity of lymphocytes to emerge from lymph nodes, reducing the number of lymphocytes (immune cells created in blood marrow) circulating in the blood. percent versus 6 percent. percent vs 18.5 percent vs 5.6

Immunity 98

Immunity Immunization 98

European Pharmaceutical Review

OCTOBER 25, 2024

The monoclonal antibody therapy was reported to be well tolerated, with most treatment emergent adverse events (TEAE) Grade 1 or 2, according to the findings. These promising data support continued evaluation of ZL-1310 as a monotherapy in the dose-expansion phase of the ongoing Phase I clinical trial and in combination.”

Chemotherapy 97

Chemotherapy Compounding Immunity Immunization 97

Express Pharma

AUGUST 8, 2024

Additionally, when compared to patients in the control arm, patients in the vibostolimab and pembrolizumab fixed-dose combination arm experienced a higher rate of adverse events (AEs) and immune-related AEs. A comprehensive analysis of this study is ongoing.

Chemotherapy 105

Chemotherapy Immunity Immunization 105

European Pharmaceutical Review

SEPTEMBER 22, 2022

The removal of HIV DNA from the cellular genome is essential to effecting a cure; the virus takes up long-term residence in tissue reservoirs, where it hides, evading the immune system and escaping antiretroviral therapy. As a result, HIV can persist in tissue reservoirs for years.

Labelling 145

Labelling Immunity Immunization 145

pharmaphorum

MAY 3, 2022

Learn all there is to know about the immune cell engager landscape, including clinical achievements, potential response predictors, and novel immune cell-based engager therapeutic discoveries. Download the full event guide to find out more. The post 4th Annual Cell Engager Summit | May 24-26 | Boston, MA appeared first on.

Immunization 52

Immunization Immunity 52

pharmaphorum

NOVEMBER 15, 2021

Arriving at a critical point for TIGIT development, the 2nd Annual TIGIT Therapies Summit is the definitive industry-led event focused on propelling this next-generation inhibitor to clinical use. Plus 2 add on workshops: • Elucidating the anti-tumor immunity of other immune checkpoint inhibitors in oncology.

Medical Schools 52

Medical Schools Immunity Immunization Hospitals 52

Pharmacy Times

OCTOBER 3, 2024

By utilizing a lower dose, patients can avoid potential adverse events and high financial burden.

Immunization 38

Immunization Immunity 38

Putting Patients First Blog

JUNE 15, 2023

Compliment inhibitors like eculizumab work to reduce immune system attacks that may contribute to MG symptoms. C5 protein inhibitors like ravulizumab work by inhibiting the C5 protein in the terminal complement cascade, a part of the body’s immune system. Online, I saw how many people had the same symptoms.”

Immunity 98

Immunity Immunization 98

The Thyroid Pharmacist

JUNE 30, 2023

However, low doses of this medication (hence, low dose naltrexone or LDN), have been found to modulate the immune system and have shown promise in improving cases of autoimmune disease. These include Crohn’s, MS, and Hashimoto’s, as well as other immune system-related conditions such as cancer and HIV/AIDS. Doses of 1.5-4.5

Compounding 98

Compounding Immunity Immunization Compounding Pharmacies 98

pharmaphorum

AUGUST 31, 2022

In May, a Phase 2 study started, comparing Kaiku’s electronic patient-reported outcome (ePRO) approach to evaluating immune-related adverse events to the standard model of care in cancer patients treated with checkpoint inhibitor drugs, with results due towards the end of 2023 or in early 2024.

Chemotherapy 116

Chemotherapy Immunity Immunization Hospitals 116

pharmaphorum

MAY 10, 2021

At the moment, there’s no indication that the cases are linked to the vaccine itself, but the EMA has asked the companies to provide “further detailed data, including an analysis of the events according to age and gender,” as it looks into the signal.

Vaccines 122

Vaccines Labelling Immunity Immunization 122

pharmaphorum

JUNE 15, 2022

Optimize the clinical application of immune checkpoint inhibitors to improve outcomes in earlier lines of therapy. Improve your drug development rationale across all lines of NSCLC and address challenges when moving therapies forward. Understand PD-1 resistance and improved dissection of patient populations.

Drug Development 105

Drug Development Immunization Immunity 105

pharmaphorum

NOVEMBER 11, 2022

Download the full event guide here for the official agenda. Marc Pelletier , Senior Principal Scientist – Translational Immune Oncology, Novartis. Kate Fitzgerald , Professor & Vice Chair, Department of Medicine, Division of Innate Immunity, University of Massachusetts Chan Medical School.

Medical Schools 52

Medical Schools Immunity Immunization Hospitals 52

Pharmacy Is Right For Me

SEPTEMBER 24, 2024

In my first year of pharmacy school, I joined UNC’s local SNPhA chapter as the Power to End Stroke Co-Chair and planned events ranging from blood pressure and blood glucose screenings to a step-challenge to get our community moving!

Diabetes 130

Diabetes Immunity Immunization 130

Pharmaceutical Technology

SEPTEMBER 13, 2022

The advent of immune checkpoint inhibition has arguably been the greatest breakthrough for the treatment of metastatic solid tumours, with durable complete responses observed across multiple cancer types. Overall survival (OS) data remains immature, with too few events for statistical analysis.

Immunity 69

Immunity Immunization Chemotherapy 69

pharmaphorum

MARCH 18, 2021

And because the vaccine is effective in preventing COVID-19 disease – which in itself is a cause of blood clots – it “likely reduces the risk of thrombotic events overall.”. PRAC meanwhile says is also looking into reports of cases of immune thrombocytopenia (ITP) with vaccines available in the US.

Vaccines 105

Vaccines Immunity Immunization 105

pharmaphorum

AUGUST 19, 2020

View the full event guide to see all the leading speakers and their agenda sessions. Yang Liu , Founder, President and Chief Scientific Officer, Oncoimmune will explore the CD24–Siglec-10 pathway as a novel innate immune checkpoint to modulate anti-tumor immunity.

Immunization 52

Immunization Immunity 52

pharmaphorum

NOVEMBER 17, 2020

Both Pfizer and Moderna vaccines use synthetic messenger RNA to activate the immune system against the virus. They both code for the “Spike” protein seen on the surface of the SARS-CoV-2 coronavirus, which causes the body to produce antibodies that neutralise the virus in the event of an infection.

Vaccines 77

Vaccines Immunity Immunization 77

Quality Matters

FEBRUARY 6, 2025

To understand monoclonal antibody drugs, its necessary to first know a little about how antibodies work in the bodys immune system. The immune system protects the body from harmful substances, microbes and abnormal cells that can cause diseases. Anything that triggers an immune response is called an antigen.

HIV Treatment and Prevention Agents 52

HIV Treatment and Prevention Agents Immunity Immunization Biosimilars 52